TW202321220A - 含吡啶基的化合物 - Google Patents

含吡啶基的化合物 Download PDF

Info

Publication number
TW202321220A
TW202321220A TW111141120A TW111141120A TW202321220A TW 202321220 A TW202321220 A TW 202321220A TW 111141120 A TW111141120 A TW 111141120A TW 111141120 A TW111141120 A TW 111141120A TW 202321220 A TW202321220 A TW 202321220A
Authority
TW
Taiwan
Prior art keywords
compound
alkyl
water
preparation
reaction
Prior art date
Application number
TW111141120A
Other languages
English (en)
Chinese (zh)
Inventor
劉飛
徐宏江
彭岩
施偉
周佳偉
顧佳佳
Original Assignee
大陸商正大天晴藥業集團股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商正大天晴藥業集團股份有限公司 filed Critical 大陸商正大天晴藥業集團股份有限公司
Publication of TW202321220A publication Critical patent/TW202321220A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW111141120A 2021-10-29 2022-10-28 含吡啶基的化合物 TW202321220A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN202111269381.X 2021-10-29
CN202111269381 2021-10-29
CN202210233624 2022-03-10
CN202210233624.2 2022-03-10
CN202210849103.X 2022-07-19
CN202210849103 2022-07-19
CN202211274771 2022-10-18
CN202211274771.0 2022-10-18

Publications (1)

Publication Number Publication Date
TW202321220A true TW202321220A (zh) 2023-06-01

Family

ID=86159245

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111141120A TW202321220A (zh) 2021-10-29 2022-10-28 含吡啶基的化合物

Country Status (11)

Country Link
US (1) US20250002472A1 (cg-RX-API-DMAC7.html)
EP (1) EP4424676A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024539922A (cg-RX-API-DMAC7.html)
KR (1) KR20240090588A (cg-RX-API-DMAC7.html)
CN (1) CN118055924A (cg-RX-API-DMAC7.html)
AU (1) AU2022376773A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235436A1 (cg-RX-API-DMAC7.html)
IL (1) IL312179A (cg-RX-API-DMAC7.html)
MX (1) MX2024004871A (cg-RX-API-DMAC7.html)
TW (1) TW202321220A (cg-RX-API-DMAC7.html)
WO (1) WO2023072248A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024222900A1 (zh) * 2023-04-28 2024-10-31 正大天晴药业集团股份有限公司 含三唑基的化合物
WO2026082075A1 (zh) * 2024-10-15 2026-04-23 杭州百诚医药科技股份有限公司 丙烯酰胺类化合物及其医药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102322794B1 (ko) * 2013-06-21 2021-11-05 카리오팜 쎄라퓨틱스, 인코포레이티드 핵수송 조절인자 및 이의 용도
US10526295B2 (en) * 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2019232724A1 (en) * 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
CN110592141B (zh) * 2018-06-13 2023-07-07 中国科学院上海有机化学研究所 用于调控基因编辑效率的化合物及其应用
WO2020092965A1 (en) * 2018-11-01 2020-05-07 Karyopharm Therapeutics Inc. E2f1 as a biomarker for treatments using xpo1 inhibitors
WO2021252900A1 (en) * 2020-06-11 2021-12-16 Karyopharm Therapeutics Inc. Biomarkers for response to exportin-1 inhibitors in multiple myeloma patients
CN112538069A (zh) * 2020-11-05 2021-03-23 苏州艾和医药科技有限公司 一种氮唑类衍生物或其药物可接受盐及其制备方法和用途
CN113045550A (zh) * 2021-03-12 2021-06-29 深圳济康医药科技有限公司 一种三氮唑类衍生物及其制备方法和应用
CN113248474A (zh) * 2021-05-24 2021-08-13 王能能 五元氮唑杂环衍生物及其制备方法和用途

Also Published As

Publication number Publication date
CN118055924A (zh) 2024-05-17
EP4424676A4 (en) 2025-11-12
WO2023072248A1 (zh) 2023-05-04
EP4424676A1 (en) 2024-09-04
CA3235436A1 (en) 2023-05-04
JP2024539922A (ja) 2024-10-31
AU2022376773A1 (en) 2024-05-23
IL312179A (en) 2024-06-01
US20250002472A1 (en) 2025-01-02
MX2024004871A (es) 2024-05-06
KR20240090588A (ko) 2024-06-21

Similar Documents

Publication Publication Date Title
TW202311260A (zh) 含有亞磺醯亞胺基的atr抑制劑化合物
CN115433179A (zh) 苯并嘧啶类化合物及其医药用途
EP4083020A1 (en) Protein degradation agent compound preparation method and application
WO2023208143A1 (zh) 一种吡唑取代环戊酯衍生物及其用途
CN115785068A (zh) Kif18a抑制剂
TW202328130A (zh) Sik抑制劑及其組合物、製備方法和用途
EP4289847A1 (en) Pim kinase inhibitor
TW202214631A (zh) 作為Akt激酶抑制劑的化合物
JP2024540511A (ja) Egfrタンパク質分解用化合物及びその使用
WO2022166741A1 (zh) 含有苯并杂环的作为egfr激酶抑制剂的大环化合物、其药物组合物和用途
EP4667469A1 (en) Compound containing trifluoromethylsulfonyl
WO2023072248A1 (zh) 含吡啶基的化合物
CN116390728A (zh) 喹唑啉衍生物及其制备方法和用途
EP4703357A1 (en) Triazolyl-containing compounds
EP4617272A1 (en) Fused bicyclic compound
CN115925689A (zh) 含环丙基的核输出蛋白抑制剂
JP2025503055A (ja) ヒドラジン基含有化合物
CN119212977A (zh) 芳基炔酰胺衍生物
TW202322812A (zh) 吡唑[3,4-d]嘧啶-3-酮類化合物、包含其的藥物組合物及其醫藥用途
HK40111379A (en) Pyridyl-containing compound
CN115703764A (zh) 含三氮唑的核输出蛋白抑制剂
CN116730984A (zh) 含吡啶基的化合物
EA051207B1 (ru) Пиридилсодержащее соединение
CN113582988B (zh) 吡啶并环类化合物及其医药用途
HK40112897A (en) Hydrazino group-containing compound